Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Cansino Biologics Inc (688185)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
51.08 -0.31    -0.60%
30/04 - Closed. Currency in CNY ( Disclaimer )
Type:  Equity
Market:  China
ISIN:  CNE100004BM0 
  • Volume: 1,567,244
  • Bid/Ask: 51.08 / 51.18
  • Day's Range: 50.07 - 51.39
Cansino Biologics 51.08 -0.31 -0.60%

Cansino Biologics Inc Company Profile

 
Get an in-depth profile of Cansino Biologics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

2291

Equity Type

ORD

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.

Contact Information

Address 401-420, Biomedical Park 4th Floor
185 South Avenue TEDA West District Tianjin, 300457
China
Phone 86 022 5821 3600
Fax 86 022 5821 3677

Top Executives

Name Age Since Title
David Briles - - Member of Scientific Advisory Board
Liang Lin 49 2013 Non-Executive Director
Wing Yu Leung 53 2015 Non-Executive Director
Shiu Kwan Wai 59 2018 Independent Non-Executive Director
Jing Wang 42 2017 Chief Commercial Officer, Deputy GM & Executive Director
Yingyu Liang 52 - Non-Executive Director
Shan Lu - 2022 Member of the Scientific Advisory Board
David Salisbury - 2023 Member of Scientific Advisory Board
Yingyu Liang 52 - Non-Executive Director
Shiu Kwan Wai 59 2018 Independent Non-Executive Director
Jingren Zhang - - Member of Scientific Advisory Board
Pierre Van Damme - 2023 Member of Scientific Advisory Board
Xuefeng Yu 59 2009 Co-Founder, Executive Chairman, CEO & GM
Dongxu Qiu 63 2009 Co-Founder, Executive VP, Deputy GM & Executive Director
Tao Zhu 50 2009 Co-Founder, Deputy GM, Chief Scientific Officer & Executive Director
Shou-Bai Chao 60 2018 COO, Deputy GM & Executive Director
Wing-Yu Leung 53 - Non-Executive Director
Wing-Yu Leung 53 - Non-Executive Director
Wing-Yu Leung 53 - Non-Executive Director
Jianzhong Liu 59 2019 Independent Non-Executive Director
Zhu Xin 55 2018 Independent Non-Executive Director
Zhi Xiao 46 2019 Chairman of Employee Representative Supervisor
Luis Barreto 71 2018 Member of Scientific Advisory Board
Shuifa Gui 59 2019 Independent Non-Executive Director
George R. Siber 79 2023 Co-Chair of Scientific Advisory Board
Leung Cheung Yiu - - Independent Non-Executive Director
Liming Li - 2023 Co-Chair of Scientific Advisory Board
Wing-Yu Leung 53 - Non-Executive Director
Wing-Yu Leung 53 - Non-Executive Director
Wing-Yu Leung 53 - Non-Executive Director
Zhongqi Shao 63 2021 Supervisor
Yuan Zhou 36 2023 Employee Representative Supervisor
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

688185 Comments

Write your thoughts about Cansino Biologics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email